Poland· PL-100333299
Lipidem
A fettemulsionen product containing triglycerida saturata media + soiae oleum raffinatum + omega-3 acidorum triglycerida, registered in Poland by B. Braun Melsungen AG. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Fettemulsionen is registered in 11 of 19 countries.
Countries holding a registration under ATC B05BA02 (fettemulsionen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Fettemulsionen · ATC B05BA02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Triglycerida saturata media + Soiae oleum raffinatum + Omega-3 acidorum triglycerida
- Manufacturer
- B. Braun Melsungen AG
- Country
- Poland (PL)
- ATC code
- B05BA02
- ATC class
- Fettemulsionen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 13
- gtin05909991204006
- gtin05909991204013
- gtin05909991204020
- gtin05909991204037
- gtin05909991204044
- gtin05909991204051
- gtin05909991204068
- gtin05909991204495
- gtin05909991204501
- gtin05909991204518
- gtin05909991204525
- gtin05909991204532
- gtin05909991204549
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B05BA02
Fettemulsionen, as other registers publish it.
- FinlandClinoleicBaxter Oy
- DenmarkClinoleicBaxter A/S
- NorwayClinoleicBaxter Medical AB
- CzechiaCLINOLEICBAXTER CZECH spol. s r.o., Praha
- CzechiaCLINOLEICBAXTER CZECH spol. s r.o., Praha
- CzechiaCLINOLEICBAXTER CZECH spol. s r.o., Praha
- CzechiaCLINOLEICBAXTER CZECH spol. s r.o., Praha
- CzechiaCLINOLEICBAXTER CZECH spol. s r.o., Praha
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/75e278bb-f8c9-4acf-8a8d-b9027f7f0503 GET /v1/drugs/75e278bb-f8c9-4acf-8a8d-b9027f7f0503?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Emulsja do infuzji",
"source": "urpl",
"strength": "200 mg/ml",
"packaging": "05909991204006 ¦ Lz ¦ 106089\n1 butelka 250 ml\n05909991204013 ¦ Lz ¦ 106090\n1 butelka 500 ml\n05909991204020 ¦ Lz ¦ 106091\n1 butelka 1000 ml\n05909991204037 ¦ Lz ¦ 106092\n6 butelek 1000 ml\n05909991204044 ¦ Lz ¦ 106093\n10 butelek 500 ml\n05909991204051 ¦ Lz ¦ 106094\n10 butelek 100 ml\n05909991204068 ¦ Lz ¦ 106095\n10 butelek 250 ml\n05909991204495 ¦ Lz ¦ Skasowane ¦ 106177\n1 poj. 250 ml\n05909991204501 ¦ Lz ¦ Skasowane ¦ 106178\n1 poj. 500 ml\n05909991204518 ¦ Lz ¦ Skasowane ¦ 106179\n1 poj. 1000 ml\n05909991204525 ¦ Lz ¦ Skasowane ¦ 106180\n10 poj. 250 ml\n05909991204532 ¦ Lz ¦ Skasowane ¦ 106181\n10 poj. 500 ml\n05909991204549 ¦ Lz ¦ Skasowane ¦ 106182\n10 poj. 1000 ml",
"substance": "Triglicerydy nasyconych kwasów tłuszczowych o średniej długości łańcucha 100 g + Oleum sojae purificatum 80 g + Omega-3 acidorum triglycerida 20 g",
"common_name": "Triglycerida saturata media + Soiae oleum raffinatum + Omega-3 acidorum triglycerida",
"pl_product_id": "100333299",
"pozwolenie_nr": "22274",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about fettemulsionen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.